Ref: PHE publications gateway number 2019226PDF, 160 KB, 15 pages
This file may not be suitable for users of assistive technology.
Request an accessible format.
If you use assistive technology (such as a screen reader) and need a
version of this document in a more accessible format, please email email@example.com.
Please tell us what format you need. It will help us if you say what assistive technology you use.
This edition includes updates on:
epidemiology of tetanus
management of tetanus prone wounds
correct dose of immunoglobulin for prevention of tetanus
use of immunoglobulins for the treatment of clinical tetanus
Tetanus is an acute disease caused by the action of tetanus toxin, released following infection by the bacterium Clostridium tetani.
In November 2018 revised guidance for healthcare professionals on the use of immunoglobulins for the treatment of clinical tetanus and the management of tetanus prone wounds was issued.